Argent Biopharma Limited has released a press release.
Ethics Committee Approval for CannEpil Phase IIb Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Argent Biopharma
- Binding Term Sheet Signed for Distribution of ArtemiC
- Voluntary Suspension
- Phase II Clinical Trial on COVID-19 Patients Commenced
- March Quarterly Activity and Cashflow Report
- Second Ethics Committee Approval for Phase II COVID-19 Trial
Later from Argent Biopharma
- 3,250 Prescriptions Milestone Surpassed
- Binding Term Sheet for distribution of CannEpil in Israel
- Sale of MGC Nutra to US CBD and Hemp Wellness Company
- MXC Awarded 3-year EU GMP Manufacturing Licence
- COVID-19 Clinical Trial Site Expansion into India
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma